about
Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinomaEGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection.Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe.Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC statusOncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerEGFR T790M mutation: a double role in lung cancer cell survival?Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR MutationSuccesses and limitations of targeted cancer therapy in lung cancer.Recent evidence, advances, and current practices in surgical treatment of lung cancer.Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.New and emerging targeted treatments in advanced non-small-cell lung cancer.Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond.CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-LetterReciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged sword.Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.Racial differences in lung cancer genetics.Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.Prognostic impact of pleural lavage cytology in patients with primary lung cancer.Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.Analysis of ERBB4 mutations and expression in japanese patients with lung cancer.[Acquired resistance mechanisms to EGFR-TKIs in EGFR mutated lung cancers].Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free interval.Impact of age on epidermal growth factor receptor mutation in lung cancer.Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and AngiogenesisA true Brunner's gland adenoma
P50
Q34406294-FF34C228-0A54-49E7-8248-766BA41A6150Q34486675-39BC0063-C069-4251-AAEF-C1382DDC5C77Q35602423-190BD414-8E7B-4D61-81C6-E5BB07AC51C2Q35995940-CC7A216B-11F8-4550-8A8E-654E8FED569DQ36051745-27E3B7F1-5F2F-4667-B5C8-9CEC02E37EA0Q36099734-87861F06-8ED7-4039-B56B-158C9C97D66BQ36247846-5A7A2248-E688-416C-8ADE-DE0A986F7834Q36278557-2967331B-9382-4B63-A463-7C6084C21791Q36801144-751C421F-553D-4A7B-BD77-C18D4CC5D820Q37354807-E4E1EBB0-BF4A-403D-9E0B-F3EF3730B8A7Q37669061-A0A6490E-A2A6-45BD-9A36-761E9A1F9DF8Q38204235-AE46DFE9-263F-4668-90A8-F00CD16C634EQ38277089-DF5D1322-1BAE-4E26-B7F4-3656314F3770Q38486882-04ABBEDA-ECCA-424B-9FBF-B468AFF2049EQ38745430-BDB42856-7FCA-4C1E-A88C-2E17C4647325Q38835312-B0EE8E93-3D99-4455-AD3D-96D1CF941E58Q38947183-16DA9313-DD4D-409B-8D16-4A8252EA3427Q38956309-8B692C8C-C138-4880-961E-36D20F769898Q38983710-E9CD44F9-38FA-4A56-AC50-D3EDF92A742BQ39031210-33002A0F-24F9-4D94-988F-8E41021C643BQ39306353-C33DFD6A-F9CE-4B4F-A3FD-6B439E86CE99Q40163911-A9FEC3B1-5B0A-4A61-8D0E-4B14FC2B0EB8Q42316038-778DF260-0980-4191-A913-C3D36BA8CA3EQ42815191-3CC6C1E3-4FD4-4A52-9577-79C9A02E9C53Q43289375-AFDA2A71-F75F-4A33-B657-6C902E03E3C5Q44933924-91FEC2AF-1C0C-4DB0-9A18-B93547EAE45CQ45193022-0E676838-E8F0-4164-AC07-DE58F6BDC1D9Q46182822-8CF34272-0428-4F64-B0BA-6343FE8A55D5Q47098234-FF92E8C3-6653-443D-8055-811E6936C6AEQ52812352-2E13A964-2E96-4DDA-AE18-2DD00595DEFDQ53150846-71211F0F-C43B-450D-BC91-939396FA6B6AQ53758782-C298547E-492B-4B51-8339-964E27F14EACQ54405040-3409A46A-6072-4C07-B4A0-801ED7BF3CC8Q54442850-777191C4-017C-454E-A910-CFEAEDDEE1F6Q54460646-17D20B3C-D0E4-43B1-8AD1-4B7F91F1C5C7Q54479769-F397F912-4054-40C9-BA01-B60500EFA2B9Q55031467-789ED0E6-FD35-46D3-AC4A-D2F6C164BCBAQ58454640-89011BB7-B58B-4172-9AEE-C662CC1160A3Q79737152-121907DD-C894-4E1C-9EA2-73F1FC760B39
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kenichi Suda
@ast
Kenichi Suda
@en
Kenichi Suda
@es
Kenichi Suda
@nl
Kenichi Suda
@sl
type
label
Kenichi Suda
@ast
Kenichi Suda
@en
Kenichi Suda
@es
Kenichi Suda
@nl
Kenichi Suda
@sl
prefLabel
Kenichi Suda
@ast
Kenichi Suda
@en
Kenichi Suda
@es
Kenichi Suda
@nl
Kenichi Suda
@sl
P106
P1153
26221498600
P31
P496
0000-0002-0842-8832